Humans *Urinary Bladder Neoplasms/surgery/pathology Neoplasm Recurrence Local/pathology Cystectomy/methods Cystoscopy/methods Light #BladderCancer #blcsm #uroonc blue light non-muscle-invasive bladder cancer photodynamic diagnosis transurethral resection of the bladder white light

Bayes Theorem Cystectomy Humans *Laparoscopy Postoperative Complications/surgery *Robotic Surgical Procedures *Robotics Treatment Outcome *Urinary Bladder Neoplasms/surgery

膀胱肿瘤 磁共振成像 膀胱影像报告和数据系统 肌层浸润 Meta分析

Bcg Bacillus Calmette–Guérin Nmibc bladder cancer checkpoint inhibition therapy nadofaragene firadenovec non muscle invasive oncolytic viruses

Cystectomy/methods Humans Quality of Life *Urinary Bladder Neoplasms/surgery *Urinary Diversion/methods *Urinary Reservoirs Continent nursing systematic review urinary diversion

Antibodies Monoclonal Humanized/*therapeutic use *Carcinoma Transitional Cell/drug therapy Humans Prognosis Retrospective Studies *Urinary Bladder Neoplasms/drug therapy Metastatic urothelial carcinoma Pembrolizumab Prognostic factor Janssen and Pfizer. Takahiro Kimura is a paid consultant/advisor of Astellas Bayer Janssen and Sanofi. Shahrokh F. Shariat is a paid as follows: Honoraria: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Consulting or Advisory Role: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Speakers Bureau: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen Movember Foundation. The other authors declare no conflicts of interest associated with this manuscript.

Humans Female Male Infant *Urinary Bladder Neoplasms/diagnosis/therapy/pathology *Carcinoma Transitional Cell/pathology Urinary Bladder/pathology Neoplasm Staging Cystoscopy Cystectomy/methods

Adjuvants Immunologic Administration Intravesical BCG Vaccine/therapeutic use Bayes Theorem *Covid-19 Duration of Therapy Humans *Mycobacterium bovis Neoplasm Invasiveness Neoplasm Recurrence Local/drug therapy Network Meta-Analysis Pandemics *Urinary Bladder Neoplasms/drug therapy *Urology

Humans Female Male *Urinary Bladder Neoplasms/etiology/microbiology RNA Ribosomal 16S/genetics Urinary Bladder/microbiology *Microbiota/genetics Bacteria/genetics Bladder cancer Gender Urinary microbiota Uropathogens of interest.

Artificial Intelligence Humans Muscles/pathology ROC Curve Sensitivity and Specificity *Urinary Bladder Neoplasms/diagnostic imaging/pathology Bladder cancer Meta-analysis Muscle invasive Radiomics Staging Systematic review

adjuvant immune checkpoint inhibitors muscle-invasive bladder cancer neoadjuvant

Humans *Carcinoma Renal Cell/surgery Prognosis Nutritional Status *Carcinoma Transitional Cell/surgery *Urinary Bladder Neoplasms Nephrectomy *Kidney Neoplasms/surgery Retrospective Studies Controlling Nutritional Status score Renal cell carcinoma Upper tract urothelial carcinoma

Aged Body Mass Index Cohort Studies Female Humans Longitudinal Studies Male Obesity/*complications Risk Factors Urinary Bladder Neoplasms/*etiology/pathology

阿司匹林 膀胱癌 meta分析 发病风险

Cohort Studies Diet Female Humans Male Prospective Studies Risk Factors Thiamine *Urinary Bladder Neoplasms/epidemiology/etiology/prevention & control Vitamin A Vitamin B 12 *Vitamin B Complex B group vitamins Bladder cancer Nutritional oncology Pooled cohort analysis

Humans Male *Urinary Bladder Neoplasms/surgery Urologic Surgical Procedures

*Carcinoma Transitional Cell/drug therapy Female Humans Immune Checkpoint Inhibitors/therapeutic use Immunotherapy *Lung Neoplasms/pathology Male Platinum/therapeutic use Programmed Cell Death 1 Receptor *Urinary Bladder Neoplasms/drug therapy

Carcinoma Transitional Cell/*pathology/*surgery Humans Kidney Neoplasms/*pathology Neoplasms Second Primary/*pathology Nephrotomy Risk Factors Stents/*adverse effects Ureteral Obstruction/etiology/*surgery Urinary Bladder Neoplasms/*pathology/*surgery carcinoma transitional cell hydronephrosis meta-analysis stents urinary bladder neoplasms

Catheterization time Conventional transurethral resection Cáncer vesical primario no músculo-infltrante Duración de la estancia hospitalaria En-bloc transurethral resection Length of hospital stay Primary non-muscle invasive bladder cancer Recurrence Recurrencia Resección transuretral convencional Resección transuretral en bloque Tiempo de sondaje

Cystectomy/adverse effects Female Humans Male Network Meta-Analysis *Urinary Bladder Neoplasms/pathology/surgery Urologic Surgical Procedures Tueb Turbt bladder cancer en bloc transurethral en bloc transurethral resection